PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.00%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
-9.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
48.96%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
53.59%
EPS growth above 1.5x GNPX's 34.62%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
51.99%
Diluted EPS growth above 1.5x GNPX's 34.62%. David Dodd would see if there's a robust moat protecting these shareholder gains.
10.21%
Share reduction more than 1.5x GNPX's 80.76%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
6.42%
Diluted share reduction more than 1.5x GNPX's 80.76%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-59.54%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.23%
Negative FCF growth while GNPX is at 7.14%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7534.43%
Negative 10Y OCF/share CAGR while GNPX stands at 91.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-15675.30%
Negative 5Y OCF/share CAGR while GNPX is at 96.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
-5709.37%
Negative 3Y OCF/share CAGR while GNPX stands at 96.26%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-6744.35%
Negative 10Y net income/share CAGR while GNPX is at 99.56%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-20067.21%
Negative 5Y net income/share CAGR while GNPX is 96.58%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-6838.40%
Negative 3Y CAGR while GNPX is 96.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
530.49%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
431.75%
Positive short-term equity growth while GNPX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-71.36%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
52.82%
We increase R&D while GNPX cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-14.04%
We cut SG&A while GNPX invests at 52.68%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.